



Friedreich's Ataxia Research Alliance

Reata Announces Positive Topline Results from the MOXIE Registrational Trial of Omaveloxolone in Patients with Friedreich's Ataxia

Dear Friends, FAMily, Volunteers, and Supporters,

Yesterday, Reata Pharmaceuticals announced in a press release that the MOXIE Registrational Trial of Omaveloxolone in Patients with Friedreich's Ataxia had positive topline results. The following is an excerpt from the release.

“The results of MOXIE represent a truly historic moment for the patients, families, and caregivers that comprise the Friedreich's ataxia community. Based on the results reported today for omaveloxolone, we are hopeful that our community will finally have its first approved therapy that can slow this relentlessly progressive disease. We are extremely proud of, and grateful for, the FA community including all those who have participated in this clinical trial and in the natural history study important in designing the trial. We are also grateful to the clinical teams who conducted the trial and to our Reata colleagues. We look forward to continuing the Reata-FARA partnership as we work in pursuit of approval of the first FA therapy.”

On behalf of the entire FA community, thank you for you part in reaching this important milestone.

With gratitude and excitement,
Jen and Ron

To read the full press release, click the image below.

